Enhancement of anti-tumour immunity in syngeneic mice after MHC class II gene transfection.
The relationship between tumorigenicity and expression of MHC class II molecules in a class II-negative murine leukaemia cell line (LBC) was studied. Analysis of structural DNA sequences encoding MHC class II proteins was performed by Southern blot with DNA isolated from both the original LB tumour and LBC cell line, digested with EcoRI, BamHI and HindIII and hybridised with specific probes for I-A alpha d and I-A beta d chains. Similar patterns were obtained for LB, LBC and normal BALB/c lymphocytes. In vitro treatment with IFN-gamma (20 - 1000 IU ml-1) failed to induce the expression of MHC class II antigens in LBC cell line. LBC cells were tri-transfected by a liposome-mediated protocol with I-A alpha d, I-A beta d genes and pSV2neo. Cells were selected for growth in medium containing Geneticin (G418). Surviving transfectants were cloned and three I-A+ clones were obtained after 20 days (LBCT cells). Syngeneic mice inoculated with 1.0 x 10(3) LBCT (I-A+) cells failed to develop a tumour, whereas the DT50 of mice injected with 1.0 x 10(6) LBCT cells was three times the value for mice injected with LBC cells (I-A-). Furthermore, specific CTL response against tumour cells was significantly enhanced upon priming with irradiated LBC-transfected cells (27 +/- 2%) compared with irradiated LBC cells (15 +/- 1.5%) in a 4 h 51Cr-release assay. It is suggested that neoexpression of MHC class II molecules enhances anti-tumour response by transforming tumour cells into professional antigen-presenting cells (APCs), which may be used to improve tumour-specific immunity in the autologous host.
Mongini
C
C
Cátedra de Immunología, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Argentina.
Sánchez Lockhart
M
M
Waldner
C I
CI
Alvarez
E M
EM
Gravisaco
M J
MJ
Roig
M I
MI
Hajos
S E
SE
D000818:Animals; D015139:Blotting, Southern; D003602:Cytotoxicity, Immunologic; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D000949:Histocompatibility Antigens Class II / Q000096:biosynthesis / Q000235:genetics* / Q000276:immunology*; D007167:Immunotherapy; D016898:Interferon-alpha / Q000494:pharmacology; D016899:Interferon-beta / Q000494:pharmacology; D007371:Interferon-gamma / Q000494:pharmacology; D015458:Leukemia, T-Cell / Q000235:genetics* / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D012680:Sensitivity and Specificity; D014162:Transfection; D014407:Tumor Cells, Cultured
D000949:Histocompatibility Antigens Class II; D016898:Interferon-alpha; D016899:Interferon-beta; D007371:Interferon-gamma